Antiviral activity of lipoxygenase against severe fever with thrombocytopenia syndrome virus

Shuang Li; Xiaojie Zheng; Yunfa Zhang; Lingyu Zhang; Tong Yang; Hao Li; Caiyu Zhou; Xiao-Ai Zhang; Li-Zeng Gao; Wei Liu

doi:10.1093/procel/pwae061

PDF(21583 KB)

Protein Cell ›› 2025, Vol. 16 ›› Issue (2) : 143-147. DOI: 10.1093/procel/pwae061

LETTER

Antiviral activity of lipoxygenase against severe fever with thrombocytopenia syndrome virus

Shuang Li¹, ,
Xiaojie Zheng¹, ,
Yunfa Zhang¹ ,
Lingyu Zhang¹ ,
Tong Yang¹^,² ,
Hao Li¹^,³ ,
Caiyu Zhou⁴ ,
Xiao-Ai Zhang¹ ,
Li-Zeng Gao⁴ ,
Wei Liu¹^,³

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Shuang Li, Xiaojie Zheng, Yunfa Zhang, Lingyu Zhang, Tong Yang, Hao Li, Caiyu Zhou, Xiao-Ai Zhang, Li-Zeng Gao, Wei Liu. Antiviral activity of lipoxygenase against severe fever with thrombocytopenia syndrome virus. Protein Cell, 2025, 16(2): 143‒147 https://doi.org/10.1093/procel/pwae061

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Chrisnasari R, Hennebelle M, Vincken JP et al. Bacterial lipoxygenases: biochemical characteristics, molecular structure and potential applications. Biotechnol Adv 2022;61:108046. CrossRef Google scholar

[2]	Horio Y, Isegawa Y, Shichiri M. Daidzein phosphorylates and activates 5-lipoxygenase via the MEK/ERK pathway: a mechanism for inducing the production of 5-lipoxygenase metabolite that inhibit influenza virus intracellular replication. J Nutr Biochem 2023;114:109276. CrossRef Google scholar

[3]	Kuhn H, Banthiya S, van Leyen K. Mammalian lipoxygenases and their biological relevance. Biochim Biophys Acta 2015;1851:308–330. CrossRef Google scholar

[4]	Li H, Zhang LK, Li SF et al. Clinical effect and antiviral mechanism of T-705 in treating severe fever with thrombocytopenia syndrome. Cell Res 2019;29:739–753.

[5]	Li H, Jiang XM, Cui N et al. Calcium channel blockers reduce severe fever with thrombocytopenia syndrome virus (SFTSV) related fatality. Signal Transduct Target Ther 2021;6:145.

[6]	Liu Q, He B, Huang SY et al. Severe fever with thrombocytopenia syndrome, an emerging tick-borne zoonosis. Lancet Infect Dis 2014;14:763–772. CrossRef Google scholar

[7]	Mashima R, Okuyama T. The role of lipoxygenases in pathophysiology;new insights and future perspectives. Redox Biol 2015;6:297–310. CrossRef Google scholar

[8]	Morita M, Kuba K, Ichikawa A et al. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell 2013;153:112–125. CrossRef Google scholar

[9]	Prigge ST, Boyington JC, Gaffney BJ et al. Structure conservation in lipoxygenases: structural analysis of soybean lipoxygenase-1 and modeling of human lipoxygenases. Proteins 1996;24:275–291. CrossRef Google scholar

[10]	Qin T, Ma R, Yin Y et al. Catalytic inactivation of influenza virus by iron oxide nanozyme. Theranostics 2019;9:6920–6935. CrossRef Google scholar

[11]	Sun Y, Qi Y, Liu C et al. Nonmuscle myosin heavy chain IIA is a critical factor contributing to the efficiency of early infection of severe fever with thrombocytopenia syndrome virus. J Virol 2014;88:237–248. CrossRef Google scholar

[12]	Yu XJ, Liang MF, Zhang SY et al. Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med 2011;364:1523–1532. CrossRef Google scholar

[13]	Yuan SF, Wen L, Chik KK et al. In silico structure-based design of antiviral peptides targeting the severe fever with thrombocytopenia syndrome virus glycoprotein gn. Viruses 2021;13:2047. CrossRef Google scholar

[14]	Zhang L, Peng X, Wang Q et al. CCR2 is a host entry receptor for severe fever with thrombocytopenia syndrome virus. Sci Adv 2023;9:eadg6856. CrossRef Google scholar